We have previously demonstrated that plasmin acts as potent proinflammatory activator of human peripheral monocytes. Here we identify the annexin A2 heterotetramer, composed of annexin A2 and S100A10, as receptor for the plasmin-induced signaling in human monocytes. Monocytes express the annexin A2 heterotetramer on the cell surface as shown by flow cytometry, fluorescence microscopy, and co-immunoprecipitation of biotinylated cell surface proteins. Binding of plasmin to annexin A2 and S100A10 on monocytes was verified by biotin transfer from plasmin labeled with a trifunctional crosslinker. Antibodies directed against annexin A2 or S100A10 inhibited the chemotaxis elicited by plasmin, but not that induced by fMLP. Further, downregulation of annexin A2 or S100A10 in monocytes by antisense oligodeoxynucleotides impaired the chemotactic response to plasmin, but not that to fMLP. Antisense oligodeoxynucleotides similarly decreased the TNF-α release by plasmin-, but not by LPS-stimulated monocytes. At the molecular level, stimulation with plasmin, but not with catalytically inactivated plasmin, induced cleavage of annexin A2 and dissociation of the heterotetramer complex. Substitution of lysine to alanine in position 27 abolished the cleavage of recombinant annexin A2 in vitro. Together, these data identify the annexin A2 heterotetramer as a signaling receptor activated by plasmin via proteolysis.
We have previously demonstrated that plasmin acts as potent proinflammatory activator of human peripheral monocytes. Here we identify the annexin A2 heterotetramer, composed of annexin A2 and S100A10, as receptor for the plasmin-induced signaling in human monocytes. Monocytes express the annexin A2 heterotetramer on the cell surface as shown by flow cytometry, fluorescence microscopy, and co-immunoprecipitation of biotinylated cell surface proteins. Binding of plasmin to annexin A2 and S100A10 on monocytes was verified by biotin transfer from plasmin labeled with a trifunctional crosslinker. Antibodies directed against annexin A2 or S100A10 inhibited the chemotaxis elicited by plasmin, but not that induced by fMLP. Further, downregulation of annexin A2 or S100A10 in monocytes by antisense oligodeoxynucleotides impaired the chemotactic response to plasmin, but not that to fMLP. Antisense oligodeoxynucleotides similarly decreased the TNF-α release by plasmin-, but not by LPS-stimulated monocytes. At the molecular level, stimulation with plasmin, but not with catalytically inactivated plasmin, induced cleavage of annexin A2 and dissociation of the heterotetramer complex. Substitution of lysine to alanine in position 27 abolished the cleavage of recombinant annexin A2 in vitro. Together, these data identify the annexin A2 heterotetramer as a signaling receptor activated by plasmin via proteolysis.
Introduction
Most cells are able to bind plasmin(ogen) with low affinity. [1] [2] [3] Generally, the membrane binding of plasmin(ogen) has been mainly regarded in terms of membrane-associated activation of fibrinolytic or proteolytic activity. [4] [5] [6] [7] However, plasmin may elicit profound functional changes in various cells implying receptor-mediated signaling. Plasmin induces neutrophil aggregation, biosynthesis of platelet-activating factor in endothelial cells, Ca 2+ signaling in platelets and endothelial cells as well as proliferation of hepatocytes. 1, 2 In monocytes plasmin triggers release of proinflammatory lipid mediators, 8 chemotaxis 9 and expression of different proinflammatory genes such as tumor necrosis factor (TNF)-α, interleukin-1, monocyte chemoattractant protein-1, CD-40 and tissue factor through activation of nuclear factor (NF)-κB 10 , JAK/STAT and p38 MAPK signaling cascades. 11 All these effects are critically dependent on the proteolytic activity and can not be mimicked neither by plasminogen nor catalytically inactivated plasmin. [8] [9] [10] Several proteins, such as α-enolase, 12, 13 annexin A2 and TIP49a on monocytic cell lines, [14] [15] [16] annexin A2 on endothelial cells, macrophages and monocytes, [16] [17] [18] S100A10 in colorectal cancer and fibrosarcoma cells, 19, 20 gp330 on kidney epithelial cells, 21 and several others 1 have been identified as plasmin(ogen) binding sites. Occasionally these binding sites have been termed receptors, yet mostly in terms of membrane-associated proteolytic activity without signal transduction function. The protease-activated receptors (PAR) 1 and PAR4 have been proposed to mediate plasmin signaling in fibroblast, platelets, 22, 23 and in transfected CHO cells. 24 Others proposed that PAR are not activated but rather truncated and inactivated by plasmin. 25 Available evidence indicates that on human monocytes the signaling plasmin receptor is distinct from PARs, 26 yet its identity remains obscure.
Annexin A2 belongs to the family of calcium-binding proteins; it is found in the cytoplasm, and complexed with S100A10 (annexin A2 light chain, p11) as annexin A2
heterotetramer in the membrane. 3, 7, 27 Annexin A2 controls endosomal membrane dynamics including multivesicular endosome biogenesis 28 as well as exocytosis in endothelial cells. 29 Nuclear annexin A2 appears to inhibit growth of LNCaP cells 30 and 16, 18, 34 On the other hand, in tumor cells plasminogen binding and activation appears to be dependent primarily on the cell surface expression of S100A10, but not of annexin A2. 19 ,20 S100A10 might also have some additional regulatory functions because it facilitates the sensory neuron-specific sodium channel expression. 35 Here we analyzed the role of annexin A2 and S100A10 in the plasmin-mediated activation of human peripheral monocytes and demonstrate that the annexin A2
heterotetramer is not only important for binding of plasmin to monocytes but it is indeed required for the plasmin-induced signaling. We also show that activation of the plasmin receptor involves proteolysis of annexin A2 and dissociation of the annexin A2
heterotetramer. Our data demonstrate that this event initiates the signaling cascade in plasmin-stimulated monocytes leading finally to full-scale proinflammatory activation.
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Material and Methods

Materials
Anti-S100A10 and CD47 mouse monoclonal antibodies (mAb) were from BD Biosciences (San Diego, CA) and RDI (Flanders, NJ), anti-annexin A2 mAbs were from BD Biosciences or Biodesign International (Saco, ME), anti-PAR1 mAbs (WEDE15) and anti-CD41 were from Immunotech (Marseille, France), CD14 mAbs from BD Biosciences. Control mouse and rabbit IgG, and PE-conjugated donkey anti-mouse and anti-rabbit IgG F(ab) 2 
Cell preparations
Monocytes and neutrophils were isolated by autologous plasma-Percoll gradient centrifugation as described; 9, 10, 26 preparations with ≥ 94% CD14 + cells were used. 
Cross-linking experiments
To prevent the proteolytical autodegradation of plasmin, the cross-linker was synthesized in two steps. First, plasminogen (2 mg) was conjugated with a 6-fold molar excess of sulfo-SBED cross-linker reagent in PBS for 30 min at 20°C. The plasminogen-crosslinker conjugate was purified using a PD-10 column (Amersham Pharmacia Biotech, Freiburg, Germany). Fractions, containing the plasminogen cross-linker were detected by protein assay and by blotting using streptavidin-horseradish peroxidase (HRP) (Calbiochem). The plasminogen cross-linker was activated using immobilized urokinase.
Human urokinase (1 mg) was coupled to agarose beads using AminoLink coupling gel.
Formation of plasmin was monitored using the chromogenic substrate S-2251. 9 The optimal conditions for the plasminogen activation were 5 min at 37°C. Urokinase was removed by centrifugation, and monocytes (20 x 10 6 cells/200 µL medium) were treated with freshly generated plasmin cross-linker (equivalent to a final concentration of 0.143 CTA U/mL) for 7 min at 37°C. The monocytes were then exposed to UV-light 0.04 J/cm 2 to activate the cross-linker. The cells were washed and lysed with buffer containing 1%
Triton X-100. 11 The biotin-labeled proteins were precipitated with streptavidin-agarose beads (Sigma) and extensively washed. The disulfide bond between plasmin and the binding proteins was cleaved by reduction in the sample loading buffer leaving the receptor proteins solely biotin-tagged. The proteins were finally separated by SDS-PAGE and identified with avidin-HRP or specific mAbs against annexin A2 or S100A10.
Analysis of protein expression
For Western blot analysis 2x10 6 monocytes/sample were lysed and resolved by 15%
Tricine-SDS-PAGE. 11 Gels were blotted onto PVDF membranes and immunostained for annexin A2 and S100A10 (BD Biosciences). The same membranes were subsequently stained with mAbs against actin (Chemicon, Temecula, CA) to ensure equal loading.
Cell surface proteins were biotinylated for 30 min at 4°C using sulfo-NHS-SS-biotin (0.25 mg/mL). Cells were lysed, the biotinylated proteins were recovered by precipitation with immobilized neutravidin. After extensive washing, the precipitated proteins were solubilized in lysis buffer containing 50 mM DTT for 1 h at 20°C. The proteins were then immunoprecipitated with anti-S100A10 mAbs and protein A/G agarose, and analyzed by immunoblotting for annexin A2 and S100A10.
For flow cytometry, cells were incubated with 5 µg/mL rabbit Abs against annexin A2 (Biodesign) or mAb against S100A10 (RDI), or control rabbit or mouse IgG (Dianova) at 4°C for 1 hour. After washing, the cells were incubated with PE-conjugated anti-mouse or anti-rabbit IgG F(ab) 2 (1:100) for 45 min at 4°C. After final washing, the cells were analyzed using a FACScan (BD Biosciences, San Jose, CA).
Immunofluorescence microscopy
Monocytes (2x10 6 ) resuspended in 800 µL RPMI were permitted to adhere on chamber slides (BD Biosciences) for 30 min; then they were fixed with paraformaldehyde and stained with Hoechst 33342 (DNA marker), rabbit anti-annexin A2 and mouse anti-S100A10 Abs. The antibodies were visualized with anti-mouse Rhodamine-Red-labeled IgG F(ab) 2 and anti-rabbit FITC-labeled IgG F(ab) 2 and analyzed with a Diaphot fluorescence microscope (Nikon, Düsseldorf, Germany).
Antisense experiments
For in vitro knockdown of annexin A2 and S100A10, phosphorothioate-modified oligodeoxynucleotides (ODN) (ThermoHybaid, Ulm, Germany) were used. The ODN were selected on the basis of the major predicted secondary structures. 36 The antisense 
Migration assays
Cell migration was evaluated using 24-well Transwell plates (Costar, Cambridge, MA) with polycarbonate membranes (pore size 5 µm). Monocytes were suspended in HBSS containing 0.4% BSA at a concentration of 2×10 6 cells/mL, and 100 µL were added to the upper compartment of each well. 9, 38 For the experiments with inhibitory antibodies, monocytes were pretreated with antibodies (10 µg/mL), which were added to the upper and lower compartments 20 min before addition of the respective chemoattractant.
PAR1-blocking mAb WEDE15 were used at a concentration of 50 µg/mL.
26
Analysis of the plasmin-mediated cleavage of annexin A2
The cDNA encoding annexin A2 was generated by RT-PCR amplification using primers 
Statistical analysis
Values shown represent mean ± SEM. Statistical significances were calculated with the Newman-Keuls test. Differences were considered significant for P < .05.
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Results
Monocytes, but not neutrophils express the annexin A2 heterotetramer
To assess the role of the annexin A2 heterotetramer in the plasmin-induced monocyte activation we analyzed the expression of annexin A2 and S100A10 in monocytes. We had previously demonstrated that plasmin triggers a true chemotaxis in monocytes but not in neutrophils. 9 Consistent with this observation, immunoblotting of monocyte cell lysates showed both, annexin A2 and S100A10 ( Figure 1A ), whereas neutrophils expressed S100A10 only faintly, and annexin A2 not at all ( Figure 1A ). Flow cytometric analysis confirmed that both annexin A2 and S100A10 are expressed on the monocyte, but not on the neutrophil membrane ( Figure 1B ).
Immunofluorescence microscopy of non-permeabilized cells showed that annexin A2
and S100A10 are colocalized on the monocyte membrane ( Figure 1C ). The physical interaction between annexin A2 and S100A10 was confirmed by antibodies directed against S100A10, which co-immunoprecipitated annexin A2 indicating that in monocytes both proteins form the annexin A2 heterotetramer ( Figure 1D ).
Biotinylation of the cell surface proteins with a sequential two-step precipitation was used to identify formation of the annexin A2 heterotetramer at the monocyte membrane.
Here we combined the selective detection of biotinylated surface proteins with co-
immunoprecipitation. These data demonstrate that S100A10 located at the monocyte membrane co-immunoprecipitated with annexin A2 indicating formation of the annexin A2 heterotetramer at the monocyte surface ( Figure 1E ).
Plasmin binds to the annexin A2 heterotetramer on the monocyte membrane
In vitro data suggest that plasmin can bind both, phospholipid-associated annexin A2 as well as S100A10. 17 We therefore tested whether such an interaction occurs also under in vivo conditions. We synthesized a bifunctional photoactivatable plasmin cross-linker, and analyzed the transfer of the biotin tag from the cross-linker to the interacting proteins.
After incubation of the monocytes with the plasmin cross-linker, the cells were lysed, the biotinylated proteins were precipitated with streptavidin and analyzed by Western blotting. Under the conditions used, staining of the membranes with avidin-HRP showed two major bands of about 36 and 11 kDa (data not shown). Immunostaining of annexin A2 and S100A10 demonstrated that the biotinylated proteins are, indeed, annexin A2 and S100A10 ( Figure 2) . Thus, plasmin interacts in vivo with both, annexin A2 and S100A10. As expected, [8] [9] [10] the lysine analogue t-AMCA (2 mM) and excess of catalytically inactivated plasmin inhibited binding of plasmin to annexin A2 and S100A10 and the subsequent biotin transfer (Figure 2 ).
Inhibition of plasmin-induced chemotaxis by neutralizing antibodies
To characterize the functional role of annexin A2 and S100A10 in plasmin-induced signaling, we analyzed the monocyte chemotaxis towards 0.43 CTA U/mL plasmin or 10 nM fMLP in the absence and presence of antibodies directed against annexin A2 or S100A10. Pretreatment of monocytes with plasmin for 30 min prior to chemotaxis led to desensitization (14.2±3.3% of positive controls, n=3). The monocyte chemotaxis induced by plasmin remained unaffected by preincubation with 10 µg/mL unspecific IgG ( Figure   3 ). However, the cell migration was significantly reduced by preincubation of the monocytes with 10 µg/mL specific antibodies against annexin A2 and S100A10 by 59.9±6.8% and by 51.4±7.9%, respectively ( Figure 3A ).
Recent data from CHO cells cotransfected with α 9 β 1 and PAR1 suggested that PAR1 might mediate the plasmin-induced CHO cell migration. 24 However, WEDE15, mAbs that block PAR1 signaling 26 had no effect on the plasmin-induced migration of monocytes suggesting that PAR1 is not involved in the plasmin-mediated signaling in human monocytes ( Figure 3A ).
We also investigated whether various integrins might be involved in the plasmininduced monocyte migration. However, none of the neutralizing mAbs (12.5 µg/mL) directed against α 1 , α v , α L , α M , β 1 , β 2 , β 3 and α v β 3 (Chemicon, BD Pharmingen) had any significant effect on the plasmin-mediated monocyte chemotaxis (data not shown)
suggesting that plasmin does not utilize any of those integrins for chemotactic signaling in human monocytes.
For
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In contrast to the plasmin-induced monocyte chemotaxis, the antibodies directed against annexin A2 or S100A10 did not impair the migration of monocytes to 10 nM fMLP ( Figure 3B ). These data suggest that both annexin A2 and S100A10 play a specific functional role in the plasmin-induced chemotactic signaling of monocytes.
Inhibition of the annexin A2 and S100A10 expression affects the plasmininduced monocyte activation
To gain further evidence for a role of the annexin A2 heterotetramer in the plasmininduced signaling in monocytes, we abrogated expression of annexin A2 and S100A10 by antisense ODN. A resting period of 12 h allowed recovery from the cellular stress caused by the ODN exposure. Western blot analysis of annexin A2 and S100A10 demonstrated that 60 h after antisense ODN pretreatment the expression levels of annexin A2 and S100A10 were significantly reduced ( Figure 4A ). Consistent with the notion that annexin A2 stabilizes S100A10, 17,39 downregulation of annexin A2 concomitanly decreased the expression of S100A10. By contrast, reduction of the S100A10 expression did not affect the expression of annexin A2 ( Figure 4A ).
We analyzed the effects of downregulation of annexin A2 or S100A10 expression on the plasmin-induced chemotaxis. Neither sense nor antisense ODN pretreatment significantly affected the non-directional cell migration, i.e. chemokinesis ( Figure 4B ).
Also pretreatment with annexin A2 or S100A10 sense ODN had no effect on the plasmin- In human monocytes plasmin stimulates multiple signaling pathways, 8, 9, 11 including activation of the transcription factor NF-κB leading to TNF-α production. 10 Therefore,
we tested the effects of downregulation of the expression of annexin A2 or S100A10 on
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the plasmin-induced expression of TNF-α. Pretreatment with ODN did not elicit any detectable TNF-α release by monocytes (data not shown). As expected, 0.43 CTA U/mL plasmin triggered TNF-α release, which was not significantly affected by pretreatment of the cells with sense ODN (Figure 4D ). The release of TNF-α was, however, significantly impaired by pretreatment with antisense ODN either to annexin A2 or S100A10 ( Figure   4D ). By contrast, the TNF-α release induced by LPS (100 ng/mL) remained unaffected (data not shown).
These data demonstrate that the plasmin-induced signaling, leading either to chemotaxis or to TNF-α expression, is critically dependent on the expression of annexin A2 and S100A10.
Plasmin induces cleavage of annexin A2
We have previously demonstrated that plasmin-induced signaling requires an intact catalytic center and that inactivated plasmin abrogates the plasmin-induced monocyte activation. [8] [9] [10] In addition, annexin A2 is a substrate for calpain 40, 41 and can be cleaved in vitro by plasmin. 42 We therefore investigated whether plasmin is able to cleave annexin A2 on the monocyte membrane. Indeed, incubation of monocytes with 0.43 CTA U/mL plasmin led to generation of an annexin A2 fragment of about 33-34 kDa ( Figure 5A ). As expected, catalytically blocked plasmin was unable to generate the cleaved annexin A2 fragment. S100A10 targets annexin A2 to the plasma membrane; 27,54 consequently, its downregulation by antisense ODN also leads to significant reduction of the annexin A2 fragment ( Figure 5A ). Thus, treatment of monocytes with plasmin leads to cleavage of annexin A2. 
From 5B). Thus, plasmin cleaves annexin A2 at a single site at lysine 27 leading to a loss of the first 27 amino acids of the N terminus of annexin A2.
Proteolytic cleavage of annexin A2 by plasmin induces dissociation of the annexin A2 heterotetramer
Protein-protein interaction studies have identified the first 14 amino acids of the Nterminal domain of annexin A2 as binding domain for S100A10. 43, 44 The proteolysis of annexin A2 at position 27 might therefore lead to dissociation of the heterotetramer complex. To address this question, we investigated whether plasmin modulates the physical interaction between annexin A2 and S100A10. The monocyte cell lysates were subjected to immunoprecipitation using S100A10 mAbs and the co-immunoprecipitated proteins were identified by immunostaining. As expected, mAbs against S100A10 co- response in human monocytes. In addition, we have shown that plasmin stimulates the p38 MAPK, but not the ERK1/2 signaling pathway in human monocytes. 11 As it has also been reported that PAR1 might be important for the plasmin-induced CHO cell migration, 24 we performed additional experiments using WEDE15, a mAb blocking PAR1 signaling, 47 in a concentration that effectively inhibits the PAR1-mediated MCP-1 induction in human peripheral monocytes. 26 Here we demonstrate that the plasminmediated monocyte chemotaxis is not impaired by the mAbs against PAR1, confirming that PAR1 is not the functional plasmin receptor in human monocytes.
Other authors concluded that plasmin actually desensitizes PAR1 by cleavage at three arginine and lysine residues located at the C-terminal end of the tethered region and N-terminal to the ligand binding sites. 25 Further, using recombinant extracellular segments of PARs as well as analysis by MALDI-TOF mass spectrometry and surface
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From plasmon resonance, it was similarly concluded that plasmin would disable PAR1 and PAR2. 48 However, cross-talk between thrombin-and plasmin-signaling cascades cannot be excluded. Thus, in endothelial cells thrombin treatment induces a rapid cell surface exposure of annexin A2, 49 identified here as a component of the plasmin receptor on monocytes. One might hypothesize that plasmin might conversely also indirectly affect the PAR1-mediated signaling. In platelets plasmin supposedly induces a moderate Ca 2+ signaling through activation of PAR4, but not PAR1. 23 In our attempt to identify the plasmin receptor on monocytes, we have carefully analyzed whether plasmin might exert its effects on monocytes, at least in part, via activation of PAR4. However, monocytes do not express PAR4 and, thus, cannot signal via this receptor. 26 One of our first indications that the annexin A2 heterotetramer may be more than a passive binding site for plasmin came with the observations that plasmin induces chemotaxis 9 and lipid-mediator release 8 in monocytes, but not in neutrophils. Western blot analysis demonstrated that monocytes express both components of the annexin A2
heterotetramer complex, whereas neutrophils express only extremely low amounts of S100A10 and no annexin A2. As to the expression of the annexin A2 protein, a recent report confirmed our observation. 50 The annexin A2 heterotetramer was originally described as an intracellular submembranous cytoskeleton-associated protein complex. 27 Meanwhile, the presence of annexin A2 and annexin A2 heterotetramer has been demonstrated at the surface of various cell types. 16, 34, 50, 51 Our flow cytometric data confirm the expression of annexin A2 and for the first time show the expression of S100A10 on the surface of human peripheral monocytes. In addition, we demonstrate the surface expression of the annexin A2 heterotetramer by three independent techniques including immunofluorescence microscopy, co-immunopreciptation of S100A10 together with annexin A2 and the combination of the latter approach with surface biotinylation.
To show that plasmin indeed binds annexin A2 and S100A10 in vivo, we synthesized a plasmin cross-linker and demonstrate transfer of the biotin tag from plasmin to annexin A2 and S100A10, indicating binding of plasmin to the annexin A2 heterotetramer. Due to its configuration, the plasmin cross-linker can react only at a maximum distance of In addition, we demonstrate that plasmin interacts with the annexin A2
heterotetramer via lysine binding sites, because the binding was abolished by the lysine analogue t-AMCA. This observation is rather important, because as shown earlier, the plasmin-induced monocyte activation can also be antagonized by lysine analogues including t-AMCA. [8] [9] [10] Unexpectedly, in Western blot a conjugated-annexin A2 protein migrated slower than the unconjugated annexin A2. This could be due to posttranslational modification of annexin A2, in particular phosphorylation at serine and tyrosine residues that have been
shown to generate such slowly migrating proteins. 52 By contrast, no phosphorylation has been reported for S100A10 and indeed no change in the apparent size of S100A10 was observed in our experiments. Annexin A2 can be phosphorylated at its N-terminus at serine 25 and probably also at serine 11 by protein kinase C (PKC) as well as at tyrosine 23 by protein tyrosine kinases of the src family. 7, 30, 31 Indeed, plasmin triggers activation of PKC, which is indispensable for the plasmin-induced chemotaxis. 9 It is plausible to hypothesize that plasmin binding might trigger a phosphorylation of annexin A2.
To gain final evidence for the hypothesis that the annexin A2 heterotetramer is indeed a signaling plasmin receptor on monocytes, we downregulated the expression of annexin A2 and S100A10 by specific phosphorothioate antisense oligodeoxynucleotides.
This approach allowed us to analyze the role of the annexin A2 heterotetramer directly in primary monocytes without the need for a model cell line. 53 A similar approach has already been used to investigate the role of annexin A2 for the binding of plasminogen to human endothelial cells. 18 Our ODN were specifically designed to target only annexin A2 or S100A10 and the sequences did not overlap with homologous proteins. The expression level of both proteins was extensively reduced. In line with our hypothesis, the plasminFor personal use only. on October 22, 2017 . by guest www.bloodjournal.org From induced monocyte activation in terms of chemotaxis and TNF-α release was impaired by pretreatment with the antisense ODN against annexin A2 and S100A10.
Due to stabilization of S100A10 by annexin A2, 39 and targeting of annexin A2 by S100A10 to the membrane, 27, 54 it is impossible to completely dissect the effect of either of the two proteins on the plasmin-induced signaling. Similarly, sterical hindrance due to the antibody binding to one component of the heterotetramer complex might impair the accessibility of the second component. This might be supported by the fact that we could not achieve any better inhibitory effects on plasmin-induced monocyte chemotaxis using a combination of annexin A2 and S100A10 antibodies (unpublished results). However, our data provide unambiguous evidence for the role of the annexin A2 heterotetramer as a signaling plasmin receptor on human peripheral monocytes.
The plasmin-mediated activation of human monocytes requires an intact catalytic center of the plasmin molecule. [8] [9] [10] On the other hand, cleavage of annexin A2 by plasmin 42 and calpain 40, 41 has been reported to occur at lysine 27, and this cleavage is known to abolish annexin A2 binding to lipid rafts. 41 Our data demonstrate that annexin A2 located at the cell surface is a substrate for plasmin. Treatment of annexin A2 either in vitro or in vivo on the monocyte membrane generated truncated annexin A2. To confirm the position of the cleavage, we created an annexin A2 mutant with substitution of lysine 27 by alanine. As expected, this annexin A2 mutant was resistant to plasmin cleavage. These data show that plasmin, similar to calpain, cleaves annexin A2 at a single site at the N-terminus. The truncated annexin A2 cannot bind S100A10, because it lacks the first 14 amino acids implicated in the S100A10 binding. 43, 44 As a consequence of this cleavage, we expected and indeed observed dissociation of the annexin A2 heterotetramer after stimulation of the monocytes with plasmin.
Together our data clearly identify the annexin A2 heterotetramer as a signaling plasmin receptor on human peripheral monocytes. Binding of plasmin to the annexin A2 heterotetramer triggers cleavage of annexin A2 at lysine 27 followed by dissociation of the heterotetramer complex, which initiates downstream signaling and finally functional responses such as chemotaxis and TNF-α release. It is possible that either S100A10, or truncated annexin A2, or both are involved in further downstream signaling.
Identification of annexin A2 heterotetramer as a signaling receptor is an important step in
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From our understanding of the plasmin-mediated proinflammatory activation of human peripheral monocytes; this mechanism might be particularly relevant in a variety of chronic inflammatory processes, including atherogenesis. Immunfluorescence microscopy. Monocytes were fixed and stained with mouse antibody against S100A10 followed by anti-mouse Rhodamine-Red-labeled IgG F(ab) 2 , and rabbit anti-annexin A2 antibody followed by anti-rabbit FITC-labeled IgG F(ab) 2 . Cells were analyzed by fluorescence microscopy. Overlay picture shows colocalization of annexin A2 and S100A10. Immunostaining for annexin A2 and S100A10 was not imitated by antibodies against p38 MAPK or actin (data not shown). (D) Co-immunoprecipitation. S100A10 and annexin A2 were immunoprecipitated from monocyte lysates using anti-S100A10 antibodies and protein A/G agarose. Immunoprecipitates were analyzed by immunoblotting using monoclonal antibodies against annexin A2 and S100A10. Input is the loading control, i.e. cell lysate. IgG is negative control. IP -Immunoprecipitation. HC and LC are IgG heavy and light chain, respectively. PAR1 immunostaining served as control. (E) Localization of the annexin A2 heterotetramer at the monocyte surface.
Monocytes were surface biotinylated, and lysed. The biotinylated proteins were precipitated with immobilized neutravidin and the cross-linker was removed by DTT.
From these recovered surface proteins, annexin A2 and S100A10 were coimmunoprecipitated using anti-S100A10 mAbs and analyzed by Western blotting.
Loading control (input, lane 1) and the immunoprecipitate (lane 2) were stained using mAbs against annexin A2 and S100A10. PAR1 immunostaining was used as control. IP CTA U/mL in the presence or absence of the inhibitor of plasmin binding, t-AMCA 2 mM, for 7 min. The cross-linker was activated by UV-light, after solubilization the biotinylated proteins were precipitated using streptavidin beads. Precipitated proteins were analyzed by immunoblotting with monoclonal antibodies against annexin A2 and S100A10.
VPLCK-plasmin -catalytically inactivated plasmin generated by pretreatment with 25 µM stopped by the addition of aprotinin (6000 KI/mL), proteins were separated on 15% SDS-PAGE, and visualized by immunoblotting using mAbs against annexin A2 and S100A10.
Antisense ODN treatment was performed as described for Figure were resolved by Tricine-SDS-PAGE and analyzed using mAbs against annexin A2 and S100A10. All data are representative of at least 3 independent experiments.
